05 August 2026 Unit 2.06/31 Lexington Drive, BELLA VISTA , NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 Company Announcements Office Australian Securities Exchange CAMBIUM BIO LIMITED (ASX: CMB) UPDATED SECURITIES...
Updated Securities Trading Policy
Filed with ASX · · 9 pages · English
Release
Earlier from Cambium Bio
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Raises A$1.0 Million via Placement
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Half Year Report and Accounts
- Cambium Bio Secures A$2.4 Million Strategic Investment
Later from Cambium Bio
- Change in Company Secretary and Communication Person
- FY26 Appendix 4G and Corporate Governance Statement
- FY26 Appendix 4E and Annual Report
- Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio